articleJournal of Clinical InvestigationMar 13, 2020BRONZE OA

The convalescent sera option for containing COVID-19

ACArturo CasadevallLPLiise‐anne Pirofski

Johns Hopkins University · Albert Einstein College of Medicine

PubMed
Indexed incrossrefdoajpubmed

Abstract

As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19. At the time of this writing, SARS-CoV-2 is spreading in multiple countries, threatening a pandemic that will affect billions of people. This virus appears to be a new human pathogen. Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs available for SARS-CoV-2, although many are in rapid development and some may be available in a short time. This Viewpoint argues that human convalescent serum is an option for prevention and treatment of COVID-19 disease that could be rapidly available when there are sufficient…

Citation impact

985
total citations
FWCI
23.84
Percentile
100%
References
33
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Pandemic
  • Coronavirus disease 2019 (COVID-19)
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Virology
  • 2019-20 coronavirus outbreak
  • Coronavirus
  • Monoclonal antibody
  • Convalescent plasma
No related works found for this paper.

Funding